Recon: FDA declines to review Soligenix’s lymphoma drug; GSK pulls out of COVID deal with Vir

ReconReconBiologicsDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy